Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Purified CD4 T Lymphocyte Infusion Can Result in Graft-Versus-Leukemia Reactivity without Gvhd by Recognition of Broadly Expressed Minor Histocompatibility Antigens in HLA Class-II

P. van Balen, MD, C.A.M. van Bergen, I. Jedema, PhD, S.A.P. van Luxemburg-Heijs, J.C. Harskamp, H.M. van Egmond, S.A.J. Veld, M. Griffioen, PhD, W.A.F. Marijt, MD, PhD, C.J.M. Halkes, MD, PhD, J.H.F. Falkenburg, MD, PhD

Blood (2012) 120 (21): 4116.

https://doi.org/10.1182/blood.V120.21.4116.4116

Published: 2012

Journal Articles

Long-Term Disease-Free Survival of Patients with AML Relapse After T-Cell-Depleted Allogeneic Stem Cell Transplantation by Re-Induction Therapy and Subsequent Interferon-Boosted Donor Lymphocyte Infusion

M. Eefting, MD, C.J.M. Halkes, MD, PhD, S. Kersting, MD, PhD, W.A.F. Marijt, MD, PhD, P.A. von dem Borne, MD, PhD, J.H. Veelken, MD, PhD, J.H.F. Falkenburg, MD, PhD

Blood (2011) 118 (21): 3064.

https://doi.org/10.1182/blood.V118.21.3064.3064

Published: 2011

Journal Articles

In Vivo T Cell Depletion Using Rabbit Derived ATG Leads to An Increased EBV-PTLD Risk Due to An Induced Imbalance Between B and T Cell Recovery Which Is Not Seen After Horse Derived ATG or Alemtuzumab

C.J.M. Halkes, MD, PhD, J.H.F. Falkenburg, MD, PhD, H.M. van Egmond, J. Olde Wolbers, C.W.J. Starrenburg, P. van Balen, MD, M. van de Meent, P.A. von dem Borne, MD, PhD, W.A.F. Marijt, MD, PhD, J.H. Veelken, MD, PhD, I Jedema, PhD

Blood (2011) 118 (21): 1979.

https://doi.org/10.1182/blood.V118.21.1979.1979

Published: 2011

Journal Articles

Post-Transplant Immune Suppressive Therapy Is Not Necessary In Related and Unrelated Reduced Intensity Conditioning Stem Cell Transplantation Using Low Dose Alemtuzumab In Vivo T Cell Depletion Combined with Alemtuzumab-Mediated In Vitro T Cell Depletion of the Graft

P.A. Von Dem Borne, MD, PhD, C.J.M. Halkes, MD, PhD, C.W.J. Starrenburg, W.A.F. Marijt, MD, PhD, J.H.F. Falkenburg, MD, PhD

Blood (2010) 116 (21): 2328.

https://doi.org/10.1182/blood.V116.21.2328.2328

Published: 2010

Journal Articles

Low Incidence of Post-Transplant EBV-Related Disease After Alemtuzumab-Mediated T Cell Depletion Is Explained by the Differential Susceptibility to Alemtuzumab of B Cells and Protective CD8 and CD4 T Cells

Constantijn J.M. Halkes, MD, PhD, Inge Jedema, PhD, Judith Olde Wolbers, Esther M van Egmond, Peter A. Von Dem Borne, MD, PhD, Erik W.A.F. Marijt, MD, PhD, J.H.Frederik Falkenburg, MD, PhD

Blood (2010) 116 (21): 2330.

https://doi.org/10.1182/blood.V116.21.2330.2330

Published: 2010

NARROW

Purified CD4 T Lymphocyte Infusion Can Result in Graft-Versus-Leukemia Reactivity without Gvhd by Recognition of Broadly Expressed Minor Histocompatibility Antigens in HLA Class-II

Long-Term Disease-Free Survival of Patients with AML Relapse After T-Cell-Depleted Allogeneic Stem Cell Transplantation by Re-Induction Therapy and Subsequent Interferon-Boosted Donor Lymphocyte Infusion

In Vivo T Cell Depletion Using Rabbit Derived ATG Leads to An Increased EBV-PTLD Risk Due to An Induced Imbalance Between B and T Cell Recovery Which Is Not Seen After Horse Derived ATG or Alemtuzumab

Post-Transplant Immune Suppressive Therapy Is Not Necessary In Related and Unrelated Reduced Intensity Conditioning Stem Cell Transplantation Using Low Dose Alemtuzumab In Vivo T Cell Depletion Combined with Alemtuzumab-Mediated In Vitro T Cell Depletion of the Graft

Low Incidence of Post-Transplant EBV-Related Disease After Alemtuzumab-Mediated T Cell Depletion Is Explained by the Differential Susceptibility to Alemtuzumab of B Cells and Protective CD8 and CD4 T Cells

Email alerts

ASH Publications

American Society of Hematology

Purified CD4 T Lymphocyte Infusion Can Result in Graft-Versus-Leukemia Reactivity without Gvhd by Recognition of Broadly Expressed Minor Histocompatibility Antigens in HLA Class-II

Long-Term Disease-Free Survival of Patients with AML Relapse After T-Cell-Depleted Allogeneic Stem Cell Transplantation by Re-Induction Therapy and Subsequent Interferon-Boosted Donor Lymphocyte Infusion

In Vivo T Cell Depletion Using Rabbit Derived ATG Leads to An Increased EBV-PTLD Risk Due to An Induced Imbalance Between B and T Cell Recovery Which Is Not Seen After Horse Derived ATG or Alemtuzumab

Post-Transplant Immune Suppressive Therapy Is Not Necessary In Related and Unrelated Reduced Intensity Conditioning Stem Cell Transplantation Using Low Dose Alemtuzumab In Vivo T Cell Depletion Combined with Alemtuzumab-Mediated In Vitro T Cell Depletion of the Graft

Low Incidence of Post-Transplant EBV-Related Disease After Alemtuzumab-Mediated T Cell Depletion Is Explained by the Differential Susceptibility to Alemtuzumab of B Cells and Protective CD8 and CD4 T Cells

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only